Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-23
2005-08-23
Helms, Larry R. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388800, C530S388850
Reexamination Certificate
active
06933368
ABSTRACT:
The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.
REFERENCES:
patent: 5147637 (1992-09-01), Wright et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 5730982 (1998-03-01), Scheinberg
patent: 5821337 (1998-10-01), Carter et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6218149 (2001-04-01), Morrison et al.
patent: 6350861 (2002-02-01), Co et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 438 312 (1991-07-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 03/016466 (2003-02-01), None
Rudikoff et al., Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Paul., Fundamental Immunology, Raven Press, NY, chapter 8, p. 242, 1993.
Co et al ., the Journal of Immunology 148:1149-1154, 2-92.
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution,”Science, 1986, 233:747-753.
Arnaout et al., “Leukocyte Adhesion Molecules Deficiency: Its Structural Basis, Pathophysiology And Implications For Modulating The Inflammatory Response,”Immunol. Rev., 1990, 114:145-180.
Burgess, “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”Journal of Cell Biology, 1990, 111:2129-2138.
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA, 1992, 89:4285-4289.
Co et al., “Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen1”Journal of Immunology, 1992, 148:1149-1154.
Daugherty et al., “Polymerase Chain Reaction Facilitates the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins,”Nucl. Acids Res., 1991, 19(9):2471-2476.
Delente, “Glycosylation revisted,”Trends in Biotechnology, 1985, 3(9):218.
Groves, et al., Production of an Ovine Monoclonal Antibody to Testosterone by an Interspecies Fusion,Hybridoma, 1987, 6(1): 71-76.
Harris, “Therapeutic Antibodies—The Coming of Age,”TIBTECH, Feb. 1993, 11:42-44.
Hird et al., “Genes and Cancer,” Chapter 17, 1990, 183.
Jones et al., “Replacing the Complementarity-determining Regions, In a Human Antibody with those from a Mouse,”Nature, 1986, 321:522-525.
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Molec. Cell. Biol., 1988, 8(3):1247-1252.
Leatherbarrow et al., “Effector Functions of a Monoclonal Aglycosylated Mouse IgG2a: Binding and Activation of Complement Component C1 and Interaction With Human Monocyte Fc Receptor,”Molec. Immunol., 1985, 22(4):407-415.
Muraoka and Shulman, “Structural Requirements for IgM Assembly and Cytolytic Activity,”J. Immunol., 1989, 142(2):695-701.
Paul, “Fundamental Immunology,” 1993, Chapter 8, p. 242, Raven Press NY.
Queen et al., “A Humanized Antibody that Binds to the Interleukin 2 Recaptor,”Proc. Natl. Acad. Sci. USA, 1989, 86:1029-1033.
Riechmann et al., “Reshaping Human Antibodies for Therapy,”Nature, 1988, 332:323-327.
Scheinberg et al., “Monoclonal Antibody M195: A Diagnostic Marker for Acute Myelogenous Leukemia,”Leukemia, 1989, 3(6):440-445.
Scheinberg et al., “A Phase I Trial of Monoclonal Antibody M195 in Acute Myelogenous Leukemia: Specific Bone Marrow Targeting and Internalization of Radionuclide,”J. Clin. Oncol., 1991, 9(3):478-490.
Sox, “Attachment of Carbohydrate to the Variable Region of Myeloma Immunoglobulin Light Chains,”Proc. Natl. Acad. Sci., 1970, 66(3):975-982.
Tanimoto et al., “Restricted Expression of an Early Myeloid and Monocytic Cell Surface Antigen Defined by Monoclonal Antibody M195,”Leukemia, 1989, 3(5):339-348.
Tao et al., “Studies of Aglycosylated Chimeric Mouse-Human IgG,”Journal of Immunology, 1989, 143:8.
Taylor et al., “Selective Removal of α Heavy-chain Glycosylation Sites Causes Immunoglobulin A Degradation and Reduced Secretion,”Molec. Cell. Biol., 1988, 8(10):4197-4203.
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozome Activity,”Science, 1988, 239:1543-1536.
Waldmann, “Monoclonal Antibodies in Diagnosis and Therapy,”Science, 1991, 252:1657-1662.
Wallick et al., “Glycosylation of a VHResidue of a Monoclonal Antibody Against (put in alpha) (1→ 6) Dextran Increases Its Affinity For Antigen,”J. Exp. Med., 1988, 168:1099-1109.
Wright et al., “Antibody Variable Region Glycosylation: Position Effects on Antigen Binding and Carbohydrate Structure,”EMBO J., 1991, 10(10):2717-2723.
Wright et al., “Identification of the C3bi Receptor Of Human Monocytes and Macrophages by using Monoclonal Antibodies,”Proc. Natl. Acad. Sci. USA, 1983, 80:5699-5703.
Wright et al., “Springer Semin Immunology,” 1993, 15:259-273.
Zoller et al., “Oligonucleotide-Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors,”Methods in Immunology, 100:469-500.
Co et al., “Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody,”Mol. Immunol., 30:1361 (1993).
Colma et al., “Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-6) dextran antibody,”Jour. Immunol., 162:2162 (1999).
Gala et al., “V region carbohydrate and antibody expression,”Jour. Immunol., 172:5494 (2004).
Co Man Sung
Queen Cary L.
Scheinberg David A.
Helms Larry R.
Memorial Sloan Kettering Cancer Center
Protein Design Labs, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Increasing antibody affinity by altering glycosylation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increasing antibody affinity by altering glycosylation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increasing antibody affinity by altering glycosylation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463864